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Previewsmechanisms that differ from those ob-
served in mice with defective lipolysis.
Taken together, the work by Albert
et al. underlines the key role of HSL for lipid
metabolism, energy homeostasis, and cell
signaling in humans. Important questions,
however, remain open: Which lipolytic
mediators are involved in the regulation
of gene transcription by nuclear recep-
tors? What are the (species-specific)
mechanistic links between HSL deficiency
insulin resistance and diabetes? What is
the molecular basis for hepatosteatosis
and dyslipidemia in humans lacking HSL?
Additional studies in humans and mice
with HSL deficiency will answer these
questions.
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The insulin-degrading enzyme (IDE) has been identified as a type 2 diabetes and Alzheimer’s disease
susceptibility gene, though its physiological function remains unclear. Maianti et al. (2014) now propose
that an IDE inhibitor may be a promising therapeutic strategy for type 2 diabetes.Insulin-degrading enzyme (IDE) is a high-
ly conserved and widely expressed Zn2+
metalloprotease first identified through
its action to degrade insulin. IDE also
degrades a variety of substrates that
share in common small size (<50 amino
acids) and a pattern of charged and
hydrophobic residues rather than being
from a particular family of proteins
(Shen et al., 2006). Interest in IDE func-
tion was prompted by genome-wide as-
sociation studies that suggested linkage
to IDE for both type 2 diabetes (Sladek
et al., 2007) and Alzheimer’s disease
(Bertram et al., 2000), although linkage
to the former has not always been repli-cated. Whether the genetic linkage of
IDE with type 2 diabetes and Alzheimer’s
disease is due to loss or gain of function
of IDE enzyme activity also remains
unclear, though investigators in the
Alzheimer’s disease field have concluded
that inactivation of IDE underlies the as-
sociation (Farris et al., 2004). Loss of
function of IDE has also been implicated
in pancreatic b cell failure, as the Ide/
mouse has impaired insulin secretion
(Steneberg et al., 2013), and an inactivat-
ing mutation in the Ide gene is respon-
sible for failed insulin secretion in the
Goto-Kakizaki (GK) rat model of type 2
diabetes (Farris et al., 2004). Moreover,genetic analysis of type 2 diabetes sus-
ceptibility variants linked the IDE gene
to impaired insulinogenic index, a dia-
betic trait that is a measure of insulin
secretion (Dimas et al., 2014). In a recent
intriguing Nature paper, Maianti et al.
(2014) propose that acute inhibition of
IDE activity may be a novel therapeutic
approach to restore postprandial hyper-
glycemia in type 2 diabetes (Maianti
et al., 2014).
Maianti et al. (2014) performed an
impressive chemical and biochemical
survey in order to select an optimal
small-molecule modulator of IDE. After
establishing ideal arrangements of the0, August 5, 2014 ª2014 Elsevier Inc. 201
Figure 1. Roles of IDE in Glucose Homeostasis, Gastric Emptying, and Regulation of Amyloidogenic Protein Levels Based on Studies with
Pharmacological IDE Inhibition or Ide Knockout Mice
IDE deficit increases the abundance and signaling of the pancreatic hormones insulin, amylin, and glucagon. Increased insulin improves glucose tolerance, and
increased amylin levels slow postprandial gastric emptying. On the right is shown that IDE deficit increases levels of amylin, a-synuclein, and Ab monomers
which, via subsequent formation of toxic oligomers, impair secretory function and survival of pancreatic b cells and neurons.
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Previewscandidate structure, the potent and selec-
tive IDE inhibitor 6bK was generated.
Administration of a single dose of 6bK in
nonfasted mice 30 min prior to an insulin
tolerance test confirmed the physiological
stability and efficiency of 6bK to inhibit
IDE activity in vivo. 6bK was then evalu-
ated in lean- or high-fat-fed mice, given
as a single dose 30 min prior to a glucose
challenge. Acute administration of 6bK
enhanced glucose tolerance to oral
glucose, notably to a greater extent in
high-fat-fed mice. However, 6bK induced
glucose intolerance when glucose was
administered by intraperitoneal (i.p.) in-
jection. Measurement of plasma levels
of the main glucose-regulating hormones
in high-fat-fed mice after i.p. glucose
delivery revealed that 6bK not only
increased circulating insulin, presumably
by decreasing its degradation, but also,
as predicted by prior structural and
in vitro studies (Shen et al., 2006),
increased glucagon and amylin (also
known as islet amyloid polypeptide
[IAPP]). The latter was shown to delay
gastric emptying, contributing to the
enhanced glucose tolerance with 6bK.
In contrast, 6bK action on glucagon
signaling was shown to be responsible
for the hyperglycemia that follows i.p.
glucose injection. In summary, acute
inhibition of IDE activity in obese mice
enhanced postprandial insulin and amy-
lin secretion, attenuating the postpran-
dial glycemic excursion presumably by
insulin-mediated suppression of hepatic
glucose release and amylin-induced de-
layed gastric emptying (Figure 1).202 Cell Metabolism 20, August 5, 2014 ª201There is an unmet need for enhanced
postprandial glucose control in type 2 dia-
betes. Therefore, the authors’ proposal
of an IDE inhibitory therapy, perhaps
in combination with a GLP-1-based ther-
apy since GLP-1 suppression of glucagon
secretion may offset increased glucagon
secretion with IDE inhibition, is an
intriguing one. However, there are some
important questions that would need to
be addressed before serious consider-
ation can be given to this strategy as a
therapy. The findings reported by Maianti
et al. (2014) draw attention to the uncer-
tainty as to how IDE influences risk for
type 2 diabetes or Alzheimer’s disease,
or indeed a full understanding of its physi-
ological role. For example, does the
inhibition of IDE increase insulin levels pri-
marily by decreasing hepatic insulin clear-
ance of insulin, and/or by decreasing
degradation of insulin in b cells to increase
insulin secretion? Of greater concern,
what would be the outcome of long-term
use of IDE inhibition on cell viability in tis-
sues that express amyloidogenic peptide
substrates of IDE (Kurochkin, 2001)?
Maianti and colleagues (Maianti et al.,
2014) considered the potential issue of
an adverse effect of IDE inhibition on
one such amyloidogenic peptide. They
reported that there was no measurable
accumulation of 6bK or increase of amy-
loid b-protein (Ab) in the brain 2 hr after in-
jection of 6bK. The pancreas did take up
6bK, however, raising concerns about
the potential accumulation of misfolded
insulin, amylin, a-synuclein, and Ab in b
cells. Indeed, given that IDE has an4 Elsevier Inc.apparent substrate preference for amyloi-
dogenic proteins (proteins with a propen-
sity to form amyloid fibrils, but of greater
concern, also membrane-permeant toxic
oligomers) (Kurochkin, 2001), IDE has
been proposed to play a role in defending
against intracellular accumulation of
these proteins, as well as cellular dys-
function and apoptosis that may follow
(Figure 1). To this end, inhibition of IDE
has been shown to increase b cell vulner-
ability to human amylin (Bennett et al.,
2003). While rodent amylin is not amyloi-
dogenic, rodent models expressing
human amylin are available, and human
islets can be evaluated after transplanta-
tion into immune-tolerant mice. Likewise,
it would be important to evaluate the
effect of long-term 6bK delivery (more
than a single dose) to mice vulnerable to
neurodegenerative diseases (e.g., ex-
pressing mutant a-synuclein or Ab). Given
that the alternative pathways for clear-
ance of amyloidogenic proteins (i.e., auto-
phagy and ubiquitin/proteasome system)
decline with aging (Koga et al., 2011),
evaluating the repercussions of long-
term administration of 6bK in aged mice
would be necessary. Moreover, it remains
critical to exclude accumulation of other
amyloidogenic proteins expressed in
potentially vulnerable tissues, such as
atrial natriuretic peptide in cardiac muscle
(Kurochkin, 2001), after repeated admin-
istrations of an IDE inhibitor.
With development of this impressive
new tool, Maianti et al. (2014) have
opened the opportunity for new lines of
investigation to shed insight into both
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Previewshow IDE functions in health and its linkage
to diabetes, as well as whether the postu-
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Bile acid metabolism is tightly controlled due to the toxic effects of bile acid overload. In this issue, research
from the Feng lab reports Shp2 as a novel integrator of hepatic bile acid and FGF15/FGF19 signaling, adding
another layer of complexity to the control of bile acid biosynthesis.Bile acids (BAs) are end products of
cholesterol metabolism but also well-
recognized signaling molecules. They are
synthesized from cholesterol in the liver,
secreted from hepatocytes into bile, and
stored in the gallbladder. After ingestion
of a meal, bile is secreted into the small
intestine, where BAs contribute to the
solubilization and absorption of lipids and
fat-soluble vitamins. The majority of BAs
are reabsorbed in the terminal ileum and
transported back to the liver via the portal
vein in a process defined as enterohepatic
circulation (Thomas et al., 2008). BAs that
escape intestinal absorption are excreted
in the feces, thus removing the excess
cholesterol from the body. Despite their
essential functions, high levels of BAs
and cholesterol contribute to multiple hu-
man metabolic diseases, including chole-
cystolithiasis (gallstones), hepatic chole-
stasis, and atherosclerosis, emphasizing
the need for a tight regulation of BA syn-
thesis. In this issue of Cell Metabolism,
Li and coauthors (Li et al., 2014) identify
Shp2 as a novel coordinator of BA homeo-stasis in the liver, adding an additional
layer of complexity to this process.
Besides their role in dietary lipid ab-
sorption, BAs function as signaling mole-
cules that activate specific receptors,
including the nuclear farnesoid X receptor
(FXR or NR1H4) and the G protein-
coupled receptor TGR5 (Thomas et al.,
2008). FXR is the major regulator of the
negative feedback loop that controls BA
synthesis. Indeed, BA-activated FXR in-
duces hepatic expression of the small
heterodimer partner (SHP or NROB2), an
atypical nuclear receptor that suppresses
BA biosynthesis by inhibiting the expres-
sion of Cyp7a1, which encodes for the
rate-limiting enzyme of this pathway. A
second mechanism for the inhibition of
BA production involves intestinal BA-
FXR signaling. Activation of enteric FXR
by BAs leads to a robust induction and
secretion of fibroblast growth factor 15/
19 (FGF15 in mouse and FGF19 in human)
(Inagaki et al., 2005). FGF15/19 is
released into the circulation and binds
to the FGFR4/b-Klotho complex on thehepatocyte cell membrane, triggering
an intracellular signaling cascade that
represses Cyp7a1 mRNA expression
and BA synthesis. Although the precise
molecular mechanisms are not yet
completely characterized, several lines
of evidence indicate that both the liver re-
ceptor homolog 1 (LRH-1 or NR5A2) and
the hepatocyte nuclear factor 4a (HNF4a
or NR2A1) are crucial transcriptional
activators of the Cyp7a1 promoter and
are required for FGF15/19 and SHP to
repress Cyp7a1 (Kir et al., 2012; Nitta
et al., 1999; Stroup and Chiang, 2000).
It has been proposed that BA-induced
FGF15/19 increases the stability of
hepatic SHP by inhibiting its proteaso-
mal degradation in an extracellular
signal-regulated kinase (ERK)-dependent
manner (Miao et al., 2009), yet other
studies suggest that FGF15/19 treatment
does not alter the affinity of SHP, HNF4a,
and LRH-1 to the Cyp7a1 promoter (Kir
et al., 2012).
Within this scenario, Li et al. identified
the Src-homology 2 domain-containing0, August 5, 2014 ª2014 Elsevier Inc. 203
